{
  "0.05U\u00b7kg-1\u00b7d-1": 0,
  "0.05~0.1U\u00b7kg-1\u00b7h-1": 1,
  "0.1U\u00b7kg-1\u00b7h-1": 2,
  "0.1~0.3 units/kg body weight": 3,
  "0.1~0.3U/(kg\u00b7d)": 4,
  "0.25~0.5U/kg": 5,
  "0.2U\u00b7kg-1\u00b7d-1": 6,
  "0.2U\u00b7kg1\u00b7d1": 7,
  "0.2~0.3 units/kg body weight": 8,
  "0.2~0.3U/(kg\u00b7d)": 9,
  "0.2~0.4 units/kg body weight": 10,
  "0.2~0.4U\u00b7kg-1\u00b7d-1": 11,
  "0.3~0.5 units/kg body weight": 12,
  "0.3~0.5U/(kg\u00b7d)": 13,
  "0.4~0.5 units per kilogram of body weight": 14,
  "0.4~0.5 units/kg body weight": 15,
  "0.4~0.5U(kg\u00b7d)": 16,
  "0.4~0.5U\u00b7kg-1\u00b7d-1": 17,
  "0.4~0.8 units/kg body weight": 18,
  "0.5 units/kg body weight": 19,
  "0.5U/(kg\u00b7d)": 20,
  "0.5mg": 21,
  "0.5mg\u00b7kg-1.d-1": 22,
  "0.5mg\u00b7kg-1d-1": 23,
  "0.5~1.0 unit/kg": 24,
  "0.5~1.0g/time": 25,
  "0.5~1g each time": 26,
  "0.5\uff5e1.01.0mg/day": 27,
  "0.6 units/(kg\u00b7day": 28,
  "0.6U/(kg\u00b7d)": 29,
  "1 hour after meal": 30,
  "1 hour of exercise per day": 31,
  "1 mg per day": 32,
  "1 or 2 times a day": 33,
  "1 time": 34,
  "1 time per day": 35,
  "1 time/day": 36,
  "1 year": 37,
  "1-2 times a day": 38,
  "1-2 units": 39,
  "1.2 mg/day": 40,
  "1.2mg": 41,
  "1.5 hours": 42,
  "1.8 mg/day": 43,
  "1.8mg": 44,
  "10 mg": 45,
  "10 mg/day": 46,
  "10 \u03bcg/time": 47,
  "10-40 \u03bcg/day": 48,
  "100 (75-150) mg per day": 49,
  "100 mg/day": 50,
  "100 mg/time": 51,
  "1000 mg to 2000 mg/day": 52,
  "1000 mg/day": 53,
  "1000 or 1500 mg/day": 54,
  "1000mg": 55,
  "100mg": 56,
  "10U": 57,
  "10mg": 58,
  "10~12 units/day": 59,
  "10~12IU": 60,
  "10~20 days": 61,
  "10~20mg": 62,
  "112mg/dl": 63,
  "12 Weeks Later": 64,
  "12 months": 65,
  "12 weeks": 66,
  "14 weeks later": 67,
  "14~ 21d": 68,
  "150 minutes of exercise per week": 69,
  "1500 mg/day": 70,
  "1500mg": 71,
  "1500~2500mg": 72,
  "15\u2013180 mg/day": 73,
  "16 weeks": 74,
  "1700 mg/day": 75,
  "1700 or 2000 mg/day": 76,
  "1700mg": 77,
  "18 weeks": 78,
  "180 mg/day (60 mg 3 times a day)": 79,
  "19.63U": 80,
  "1hPG": 81,
  "1~2 hPG": 82,
  "1~2 times": 83,
  "1~2 times/day": 84,
  "1~2U": 85,
  "1~3 times": 86,
  "1~3a": 87,
  "1~4 units": 88,
  "1~4IU": 89,
  "1~4U": 90,
  "1~4th period": 91,
  "1~5th period": 92,
  "2 hPG": 93,
  "2 months later": 94,
  "2 times": 95,
  "2 times a day": 96,
  "2 times/day": 97,
  "2 to 5 days": 98,
  "2 years": 99,
  "2-3 times a day": 100,
  "2-4 units": 101,
  "2. Diabetes": 102,
  "2. Sugar": 103,
  "2.5 mg": 104,
  "2.5 mg/day": 105,
  "2.5mg": 106,
  "2.5\uff5e5.0g\uff0fd": 107,
  "2.7 years": 108,
  "20 mg": 109,
  "2000 mg/day": 110,
  "2000mg": 111,
  "20g": 112,
  "20~40mg": 113,
  "20~50rnl": 114,
  "24 months": 115,
  "24 weeks": 116,
  "24h blood sugar": 117,
  "25 mg": 118,
  "2500 mg/day": 119,
  "2550 mg/day": 120,
  "25mg": 121,
  "25\u201350 mg/day": 122,
  "27 weeks": 123,
  "270 mg/day": 124,
  "29 weeks": 125,
  "2h": 126,
  "2h blood glucose after glucose load": 127,
  "2h blood glucose after glucose load (2hPG)": 128,
  "2h blood sugar": 129,
  "2hPG": 130,
  "2hPG or random blood glucose": 131,
  "2~3 months": 132,
  "2~3 times": 133,
  "2~3 times/day": 134,
  "2~3U": 135,
  "2~4 units": 136,
  "2~4IU": 137,
  "2~4mg": 138,
  "2~6U": 139,
  "3 months": 140,
  "3 months and above": 141,
  "3 or more phases": 142,
  "3 times a day": 143,
  "3 times/day": 144,
  "3.0 mg/day": 145,
  "30 to 20 mg/day": 146,
  "300 mg/day": 147,
  "300mg": 148,
  "30~60min": 149,
  "30\u201335 mg/day": 150,
  "3IU": 151,
  "3~4 hours": 152,
  "3~4:1": 153,
  "3~5 days in total": 154,
  "3~5th period": 155,
  "3~6 months": 156,
  "3~6IU": 157,
  "4-6 units": 158,
  "4.3 years": 159,
  "40 \u03bcg": 160,
  "40u or above": 161,
  "4U": 162,
  "4mg": 163,
  "4th phase": 164,
  "4~5th period": 165,
  "4~6U": 166,
  "5 mg": 167,
  "5 mg/day": 168,
  "5 years": 169,
  "5% or 10% glucose": 170,
  "5%~10% glucose solution": 171,
  "5-10 days": 172,
  "5-hydroxytryptamine 2 (5-HT2) receptor antagonists": 173,
  "5.9~8.7U/d": 174,
  "50 mg/day": 175,
  "50% Glucose": 176,
  "50% glucose solution": 177,
  "50-100 mg/time": 178,
  "500 mg/day": 179,
  "500mg": 180,
  "500~2000mg": 181,
  "500\u20132000 mg/day": 182,
  "50mg": 183,
  "50~100mg": 184,
  "50~75mg": 185,
  "50\u2013100 mg": 186,
  "50\u2013100 mg/day": 187,
  "52 weeks": 188,
  "5mg": 189,
  "5th issue": 190,
  "5~8h": 191,
  "6 months": 192,
  "6 weeks": 193,
  "60 mg before meals": 194,
  "60 mg per meal": 195,
  "600 mg/day": 196,
  "60ml": 197,
  "7-10 days": 198,
  "75 mg/day": 199,
  "75-325 mg/day": 200,
  "75\u2013150 mg/day": 201,
  "75\u2013325 mg/day": 202,
  "7d": 203,
  "8 weeks": 204,
  "850mg": 205,
  "8mg": 206,
  "90 mg/day (30 mg 3 times a day)": 207,
  "<1\uff5e2g\uff0fd": 208,
  "<2g/d": 209,
  "<50 U/d": 210,
  ">2g\uff0fd": 211,
  ">3g/d": 212,
  "A diet high in fat": 213,
  "A diet that is mainly based on carbohydrates": 214,
  "ABI": 215,
  "ACEI": 216,
  "ACEI/ARB": 217,
  "ACR": 218,
  "ACS": 219,
  "ALT": 220,
  "ARB": 221,
  "ARB/ACEI drugs": 222,
  "ARBs": 223,
  "ASCVD": 224,
  "Abdominal": 225,
  "Abdominal bloating": 226,
  "Abdominal cavity": 227,
  "Abdominal discomfort": 228,
  "Abdominal gland": 229,
  "Abdominal gland inflammation": 230,
  "Abdominal obesity": 231,
  "Abducens nerve": 232,
  "Abnormal blood sugar": 233,
  "Abnormal bowel movements": 234,
  "Abnormal cardiopulmonary function": 235,
  "Abnormal early phase insulin secretion": 236,
  "Abnormal feeding due to early pregnancy symptoms (such as morning sickness)": 237,
  "Abnormal glucose metabolism": 238,
  "Abnormal heart function": 239,
  "Abnormal insulin secretion in \u03b2 cells": 240,
  "Abnormal lipid metabolism": 241,
  "Abnormal liver and kidney function": 242,
  "Abnormal liver function": 243,
  "Abnormal metabolism of micronutrients": 244,
  "Abnormal renal function": 245,
  "Abnormal sweating": 246,
  "Abnormal taste or smell": 247,
  "Absence of dorsalis pedis artery pulse": 248,
  "Absolute lack of insulin secretion": 249,
  "Acarbose": 250,
  "Acroarticular arteries": 251,
  "Acrogangrene": 252,
  "Activation of the local renin-angiotensin-aldosterone system": 253,
  "Active liver disease": 254,
  "Active peptic ulcer/bleeding": 255,
  "Activity": 256,
  "Acute ASCVD": 257,
  "Acute Coronary Syndrome (ACS)": 258,
  "Acute HUA": 259,
  "Acute and chronic": 260,
  "Acute and chronic heart failure": 261,
  "Acute and chronic inflammatory damage to joint cartilage, bone, kidney, and vascular endothelium": 262,
  "Acute and chronic inflammatory injury": 263,
  "Acute and chronic metabolic acidosis": 264,
  "Acute and chronic renal failure": 265,
  "Acute and chronic uric acid (salt) nephropathy": 266,
  "Acute arthritis": 267,
  "Acute attack of gouty arthritis": 268,
  "Acute complications of diabetes": 269,
  "Acute decompensated heart failure": 270,
  "Acute glomerular hyperfiltration phase": 271,
  "Acute gout": 272,
  "Acute gouty arthritis": 273,
  "Acute heart failure": 274,
  "Acute ischemic stroke": 275,
  "Acute kidney injury": 276,
  "Acute limb ischemia": 277,
  "Acute liver failure": 278,
  "Acute metabolic disturbances": 279,
  "Acute myocardial infarction": 280,
  "Acute obstruction": 281,
  "Acute pancreatitis": 282,
  "Acute phase": 283,
  "Acute uric acid nephropathy": 284,
  "Adaptive changes in intestinal flora structure after dietary changes": 285,
  "Adjust your diet": 286,
  "Adult": 287,
  "Advanced CKD": 288,
  "Advanced chronic kidney disease": 289,
  "Advanced chronic urate nephropathy": 290,
  "Advanced diabetic glomerulosclerosis": 291,
  "Adverse pregnancy": 292,
  "Adverse reactions to blood sugar": 293,
  "Affects the excretion of uric acid": 294,
  "Age-related macular degeneration": 295,
  "Aggravated proteinuria and progression of glomerular and tubulointerstitial fibrosis": 296,
  "Aggravation of pancreatic \u03b2-cell damage": 297,
  "Alanine aminotransferase (ALT)": 298,
  "Albiglutide": 299,
  "Albumin/creatinine ratio": 300,
  "Albuminuria": 301,
  "Alcohol": 302,
  "Alcohol intake": 303,
  "Alcoholic liver disease": 304,
  "Aldose reductase inhibitors": 305,
  "Aldosterone receptor antagonists (MRA)": 306,
  "Aliskiren": 307,
  "Alkalinize urine": 308,
  "All-cause death": 309,
  "Allergic claudication": 310,
  "Allergic reaction": 311,
  "Allergic reaction to fur": 312,
  "Allergic reactions": 313,
  "Allopurinol": 314,
  "Alogliptin": 315,
  "Alpha-glucosidase inhibitors": 316,
  "Alpha-lipoic acid": 317,
  "Alprostadil": 318,
  "Alternate-day fasting intervention": 319,
  "Alzheimer's disease": 320,
  "Amitriptyline": 321,
  "Amlodipine": 322,
  "Amputation": 323,
  "Amputation/toe surgery": 324,
  "Analgesics": 325,
  "Androgens": 326,
  "Angina": 327,
  "Angioedema": 328,
  "Angiogenesis": 329,
  "Angiotensin II receptor blockers (ARBs)": 330,
  "Angiotensin II receptor blockers (ARBs) antihypertensive drugs": 331,
  "Angiotensin-converting enzyme inhibitors (ACEIs)": 332,
  "Ankle": 333,
  "Ankle artery systolic pressure": 334,
  "Ankle reflexes": 335,
  "Anti-AGE drugs": 336,
  "Anti-VEGF drugs": 337,
  "Antiandrogen drugs": 338,
  "Antibody": 339,
  "Antibody positive rate": 340,
  "Anticoagulation": 341,
  "Antifibrotic drugs": 342,
  "Antiplatelet therapy": 343,
  "Anuria": 344,
  "Arrhythmias": 345,
  "Arterial blood gas": 346,
  "Arterial color Doppler ultrasonography": 347,
  "Arterial narrowing or blockage": 348,
  "Arterial pH": 349,
  "Arteries and veins": 350,
  "Arteriolar atherosclerosis": 351,
  "Arteriovenous vascular disease": 352,
  "Articular cartilage": 353,
  "Articular cartilage margin": 354,
  "Articular surface": 355,
  "Assessment of cardiovascular risk factors": 356,
  "Assessment of glucose metabolism status": 357,
  "Asymptomatic HUA": 358,
  "Asymptomatic cerebral infarction": 359,
  "Asymptomatic myocardial infarction": 360,
  "Atherosclerosis": 361,
  "Atherosclerotic cardiovascular and cerebrovascular diseases": 362,
  "Atherosclerotic cardiovascular disease": 363,
  "Atherosclerotic cardiovascular disease (ASCVD)": 364,
  "Atherosclerotic plaque": 365,
  "Atherosclerotic vascular disease": 366,
  "Atorvastatin": 367,
  "Atrasentan": 368,
  "Atrial fibrillation": 369,
  "Atrophy": 370,
  "Auricle": 371,
  "Autoantibodies": 372,
  "Autoimmune polyglandular disease": 373,
  "Autonomic nerve damage": 374,
  "Autonomic nerves": 375,
  "Autonomic neuropathy": 376,
  "Autonomic symptoms": 377,
  "Average blood sugar": 378,
  "Avoid passive smoking": 379,
  "Avoid pregnancy": 380,
  "Avoid prolonged sitting": 381,
  "Avoid smoking and excessive drinking": 382,
  "Axon": 383,
  "Axonal degeneration": 384,
  "Azotemia": 385,
  "B-ultrasound": 386,
  "Bad eating habits (monotonous diet structure, unreasonable eating method)": 387,
  "Bai Xintong": 388,
  "Bariatric Surgery": 389,
  "Bariatric metabolic surgery": 390,
  "Basal + mealtime insulin": 391,
  "Basal insulin": 392,
  "Basal-meal insulin": 393,
  "Basement membrane thickening": 394,
  "Basic heart function": 395,
  "Basic islets": 396,
  "Basic treatment": 397,
  "Batroxobin": 398,
  "Before pregnancy": 399,
  "Behavioral changes": 400,
  "Behavioral interventions": 401,
  "Being underweight": 402,
  "Benazepril": 403,
  "Benzbromarone": 404,
  "Beprostaglandin Sodium": 405,
  "Beprostaglandin Sodium Tablets": 406,
  "Beraprost Sodium": 407,
  "Beta-blockers": 408,
  "Bevacizumab": 409,
  "Bezafibrate": 410,
  "Biguanides": 411,
  "Bisoprolol": 412,
  "Bisphosphonates": 413,
  "Bladder cancer": 414,
  "Bladder residual urine": 415,
  "Bleeding": 416,
  "Bleeding spots": 417,
  "Blocked arteries": 418,
  "Blood LDL-C": 419,
  "Blood Stasis Diabetic Peripheral Neuropathy": 420,
  "Blood collection": 421,
  "Blood concentration": 422,
  "Blood gas analysis": 423,
  "Blood glucose": 424,
  "Blood glucose monitoring": 425,
  "Blood ketone bodies": 426,
  "Blood ketones": 427,
  "Blood lipid test": 428,
  "Blood lipids": 429,
  "Blood oxygen": 430,
  "Blood pH": 431,
  "Blood pressure reduction": 432,
  "Blood pressure testing": 433,
  "Blood protein": 434,
  "Blood stasis": 435,
  "Blood sugar 1 hour after meal": 436,
  "Blood sugar control": 437,
  "Blood sugar levels": 438,
  "Blood sugar reduction": 439,
  "Blood sugar related tests": 440,
  "Blood sugar standard rate": 441,
  "Blood supply cannot be restored": 442,
  "Blood triglycerides": 443,
  "Blood uric acid level": 444,
  "Blood vessel": 445,
  "Blood vessel damage": 446,
  "Blood volume expansion": 447,
  "Blood, urine, or imaging tests": 448,
  "Body coldness": 449,
  "Body mass index (BMI)": 450,
  "Bone": 451,
  "Bone and joint": 452,
  "Bone and joint destruction": 453,
  "Bone and joint diseases": 454,
  "Bone destruction": 455,
  "Bone diseases": 456,
  "Bone marrow suppression": 457,
  "Both lower limbs": 458,
  "Brain Death": 459,
  "Brain damage": 460,
  "Brain dysfunction": 461,
  "Breast": 462,
  "Breast cancer": 463,
  "Brittle diabetes": 464,
  "Broken skin on the feet": 465,
  "Bronchial hypersensitivity reaction": 466,
  "Brown urine": 467,
  "Buerger test": 468,
  "Burning pain": 469,
  "Burning sensation": 470,
  "C-Peptide": 471,
  "C-peptide concentration": 472,
  "CCB": 473,
  "CGM": 474,
  "CHD": 475,
  "CHF": 476,
  "CKD": 477,
  "CKD Stages 1-3": 478,
  "CKD stage 1-2": 479,
  "CKD stage 1-3": 480,
  "CKD stage 1-3a": 481,
  "CKD stage 3": 482,
  "CKD stage 3 and 4": 483,
  "CKD stage 3-4": 484,
  "CKD stage 3a": 485,
  "CKD stage 4": 486,
  "CKD stage 4-5": 487,
  "CKD stage 5": 488,
  "CKD stages 1 to 4": 489,
  "CKD stages 1 to 5": 490,
  "CKDI~2": 491,
  "CLP-1 receptor agonists": 492,
  "COX-2 Inhibitors": 493,
  "CRD": 494,
  "CRD intervention": 495,
  "CSII": 496,
  "CS\u2161": 497,
  "CT": 498,
  "CT angiography (CTA)": 499,
  "CT value": 500,
  "CTA": 501,
  "CVD": 502,
  "Calcium": 503,
  "Calcium Dobesilate": 504,
  "Calcium dobesilate (Dosingmin)": 505,
  "Calf": 506,
  "Canagliflozin": 507,
  "Candesartan": 508,
  "Candidal balanitis": 509,
  "Capillary blood glucose before meals": 510,
  "Capillary blood glucose before meals, before bedtime and at night": 511,
  "Capsaicin": 512,
  "Captopril": 513,
  "Cardiac autonomic neuropathy": 514,
  "Cardiac events": 515,
  "Cardiovascular": 516,
  "Cardiovascular and cerebrovascular": 517,
  "Cardiovascular and cerebrovascular atherosclerosis": 518,
  "Cardiovascular and cerebrovascular diseases": 519,
  "Cardiovascular and cerebrovascular events": 520,
  "Cardiovascular and metabolic diseases": 521,
  "Cardiovascular autonomic neuropathy": 522,
  "Cardiovascular complications": 523,
  "Cardiovascular death": 524,
  "Cardiovascular disease": 525,
  "Cardiovascular disease (CVD)": 526,
  "Cardiovascular endpoints": 527,
  "Cardiovascular events": 528,
  "Cardiovascular hazards": 529,
  "Cardiovascular risk": 530,
  "Cardiovascular system": 531,
  "Cardiovascular system diseases": 532,
  "Carotid artery": 533,
  "Carotid artery color Doppler ultrasound": 534,
  "Carotid artery stenosis": 535,
  "Carotid artery ultrasound": 536,
  "Causes pathological changes such as high glomerular pressure, chronic inflammatory response, and interstitial fibrosis": 537,
  "Causes vasomotor dysfunction": 538,
  "Ccr": 539,
  "Celecoxib": 540,
  "Cell-crystal interactions": 541,
  "Central nervous system sensory pathway lesions": 542,
  "Central obesity": 543,
  "Centrality": 544,
  "Cerebral arteries": 545,
  "Cerebral arteriosclerosis": 546,
  "Cerebral hemorrhage": 547,
  "Cerebral infarction": 548,
  "Cerebrovascular": 549,
  "Cerebrovascular disease": 550,
  "Cerebrovascular injury": 551,
  "Cervical and Lumbar Spine": 552,
  "Changes in renal function": 553,
  "Charcot arthropathy": 554,
  "Chemoradiation": 555,
  "Chemotherapy": 556,
  "Child-Pugh classification A/B": 557,
  "Chlorpropamide": 558,
  "Cholesterol absorption inhibitors": 559,
  "Cholesterol levels": 560,
  "Cholesterol-lowering drugs": 561,
  "Cholesterol-lowering medications": 562,
  "Chronic": 563,
  "Chronic Kidney Disease (CKD)": 564,
  "Chronic Kidney Disease Stage 3a": 565,
  "Chronic arterial occlusive disease": 566,
  "Chronic arthritis": 567,
  "Chronic cardiovascular disease": 568,
  "Chronic complications of diabetes": 569,
  "Chronic diabetes": 570,
  "Chronic excess energy intake": 571,
  "Chronic gouty arthritis": 572,
  "Chronic heart failure": 573,
  "Chronic hepatitis": 574,
  "Chronic inflammation": 575,
  "Chronic inflammatory demyelinating multiple": 576,
  "Chronic inflammatory demyelinating polyradiculoneuropathy": 577,
  "Chronic kidney disease": 578,
  "Chronic kidney disease (CKD)": 579,
  "Chronic obstruction": 580,
  "Chronic obstructive": 581,
  "Chronic obstructive pulmonary disease": 582,
  "Chronic renal failure": 583,
  "Chronic renal insufficiency": 584,
  "Chronic stable angina": 585,
  "Chronic urate nephropathy": 586,
  "Cilostazol": 587,
  "Citric acid mixture": 588,
  "Clearance determination": 589,
  "Clinical diabetic nephropathy": 590,
  "Clopidogrel": 591,
  "Clopidogrel bisulfate": 592,
  "Co-infection": 593,
  "Cognitive dysfunction": 594,
  "Cognitive impairment": 595,
  "Cognitive-behavioral and psychological interventions": 596,
  "Colchicine": 597,
  "Cold": 598,
  "Cold feeling": 599,
  "Color Doppler ultrasound": 600,
  "Colorectal": 601,
  "Colorectal cancer": 602,
  "Combined hyperlipidemia": 603,
  "Combining diet with exercise": 604,
  "Common peroneal nerve": 605,
  "Compartment syndrome": 606,
  "Compensated cirrhosis": 607,
  "Compensation period": 608,
  "Compensatory appetite": 609,
  "Compensatory hypersecretion of insulin": 610,
  "Complete pancreatic islet failure": 611,
  "Completely hyposecretion state": 612,
  "Complicated kidney stones": 613,
  "Complications of diabetes": 614,
  "Composite cardiovascular endpoint": 615,
  "Compound Danshen Dripping Pills": 616,
  "Compound muscle action potential": 617,
  "Compression": 618,
  "Compression neuropathy": 619,
  "Compression stockings": 620,
  "Concentration 1U/ml": 621,
  "Conduction velocity": 622,
  "Congestive": 623,
  "Congestive heart failure": 624,
  "Congestive heart failure (CHF)": 625,
  "Connective tissue": 626,
  "Connective tissue diseases": 627,
  "Continuous intravenous drip": 628,
  "Continuous intravenous insulin infusion": 629,
  "Continuous subcutaneous infusion": 630,
  "Continuous subcutaneous insulin infusion (CSH)": 631,
  "Contraceptive pills": 632,
  "Contrast agents": 633,
  "Contrast-induced acute kidney injury": 634,
  "Control blood sugar": 635,
  "Control body mass": 636,
  "Control of stress": 637,
  "Controlled release (glipizide)": 638,
  "Coolness in lower limbs": 639,
  "Coronary CT imaging": 640,
  "Coronary angiography": 641,
  "Coronary arteries": 642,
  "Coronary atherosclerosis": 643,
  "Coronary events": 644,
  "Coronary heart disease": 645,
  "Coronary revascularization": 646,
  "Cotton-wool spots": 647,
  "Cr": 648,
  "Cranial Neuropathy": 649,
  "Cranial nerves": 650,
  "Creatine kinase": 651,
  "Creatinine": 652,
  "Creatinine clearance": 653,
  "Cross allergic reaction": 654,
  "CxC": 655,
  "Cystatin C": 656,
  "Cystatin C (CysC)": 657,
  "D PP-4i": 658,
  "DKA": 659,
  "DKA during pregnancy": 660,
  "DKD": 661,
  "DPN": 662,
  "DPP-4 enzyme inhibitors": 663,
  "DPP-4 inhibitors": 664,
  "DPP-4i": 665,
  "DR": 666,
  "DSA": 667,
  "DSME": 668,
  "DSME/S": 669,
  "Daily Health": 670,
  "Daily blood sugar": 671,
  "Daily blood sugar variability": 672,
  "Daily care": 673,
  "Daily dosage up to 1000 mg": 674,
  "Damage to endothelial cells": 675,
  "Damage to liver and kidney function": 676,
  "Damage to mesangial cells and podocytes": 677,
  "Damage to the optic nerve": 678,
  "Danhong injection": 679,
  "Dapagliflozin": 680,
  "Darkening of the extremities": 681,
  "Decline of pancreatic \u03b2-cell function": 682,
  "Decompensated": 683,
  "Decompensated cirrhosis": 684,
  "Decompensated heart failure": 685,
  "Decompensation": 686,
  "Decreased ability to protect against self-harm and other injuries": 687,
  "Decreased appetite": 688,
  "Decreased autologous \u03b2-cell function": 689,
  "Decreased blood flow to peripheral nerves": 690,
  "Decreased blood volume": 691,
  "Decreased cardiopulmonary function": 692,
  "Decreased gastrointestinal emptying function": 693,
  "Decreased insulin secretion rate": 694,
  "Decreased kidney function": 695,
  "Decreased liver and kidney function": 696,
  "Decreased nitric oxide production": 697,
  "Decreased or absent sensation": 698,
  "Decreased or absent tendon reflexes": 699,
  "Decreased sensation of vibration, pain, touch, pressure, and temperature": 700,
  "Decreased skin temperature": 701,
  "Decreased solubility and supersaturation of uric acid in urine": 702,
  "Decreased vitamin B12 levels": 703,
  "Deep tissue damage": 704,
  "Deep vein thrombosis": 705,
  "Deep veins": 706,
  "Defective insulin secretion": 707,
  "Defective \u03b2-cell function": 708,
  "Defective \u03b2-cell insulin secretion": 709,
  "Degeneration": 710,
  "Degeneration of cervical and lumbar spine": 711,
  "Delayed peak glucose load": 712,
  "Demyelination of nerve fibers": 713,
  "Dental Care": 714,
  "Depression": 715,
  "Desquamative skin lesions": 716,
  "Destruction of articular cartilage": 717,
  "Develop a comprehensive pregnancy follow-up plan": 718,
  "Develop a pregnancy plan as a family unit": 719,
  "Develop new management plans and educational support programs": 720,
  "Diabetes": 721,
  "Diabetes Education": 722,
  "Diabetes Storage Disease": 723,
  "Diabetes duration": 724,
  "Diabetes microcirculatory disorders": 725,
  "Diabetes self-management education/support (DSME/S)": 726,
  "Diabetes that is missed, undiagnosed, or untreated during pregnancy": 727,
  "Diabetes-lowering drugs": 728,
  "Diabetic": 729,
  "Diabetic Bullous Disease": 730,
  "Diabetic Glomerulonephropathy": 731,
  "Diabetic Kidney Disease (DKD)": 732,
  "Diabetic Macular Edema": 733,
  "Diabetic Nephropathy": 734,
  "Diabetic Retinopathy": 735,
  "Diabetic Retinopathy (DR)": 736,
  "Diabetic amyotrophy": 737,
  "Diabetic autonomic neuropathy": 738,
  "Diabetic cardiomyopathy": 739,
  "Diabetic chronic kidney disease (CKD)": 740,
  "Diabetic distal symmetric polyneuropathy (DSPN)": 741,
  "Diabetic foot": 742,
  "Diabetic foot disease": 743,
  "Diabetic foot infection": 744,
  "Diabetic foot ulcer": 745,
  "Diabetic glomerulopathy": 746,
  "Diabetic high risk foot": 747,
  "Diabetic ketoacidosis": 748,
  "Diabetic kidney damage": 749,
  "Diabetic kidney disease": 750,
  "Diabetic kidney disease (DKD)": 751,
  "Diabetic lower extremity vascular disease": 752,
  "Diabetic macroangiopathy": 753,
  "Diabetic microangiopathy": 754,
  "Diabetic microvascular complications": 755,
  "Diabetic mononeuropathy": 756,
  "Diabetic nephropathy": 757,
  "Diabetic neuropathy": 758,
  "Diabetic peripheral neuropathy": 759,
  "Diabetic peripheral neuropathy (DPN)": 760,
  "Diabetic peripheral vascular disease": 761,
  "Diabetic peripheral vascular occlusive disease": 762,
  "Diabetic pregnancy": 763,
  "Diabetic radiculoplexopathy": 764,
  "Diabetic retinopathy": 765,
  "Diabetic retinopathy (DR)": 766,
  "Diabetic vascular disease": 767,
  "Dialysis": 768,
  "Dialysis treatment": 769,
  "Diastolic blood pressure": 770,
  "Diclofenac": 771,
  "Diet": 772,
  "Diet and exercise": 773,
  "Diet and exercise intervention": 774,
  "Diet and exercise interventions": 775,
  "Diet and exercise therapy": 776,
  "Diet combined with exercise therapy": 777,
  "Diet control": 778,
  "Diet management": 779,
  "Diet therapy": 780,
  "Diet therapy alone": 781,
  "Dietary approaches to stop hypertension": 782,
  "Dietary factors": 783,
  "Dietary fiber": 784,
  "Dietary intervention": 785,
  "Dietary management": 786,
  "Dietary structure of the population": 787,
  "Difamin": 788,
  "Difficulty in wound healing": 789,
  "Difficulty swallowing": 790,
  "Difficulty urinating": 791,
  "Digestive tract": 792,
  "Digital Subtraction Angiography (DSA)": 793,
  "Dihydropyridine calcium antagonists": 794,
  "Dihydropyridine calcium channel blockers": 795,
  "Dihydropyridines": 796,
  "Diltiazem?": 797,
  "Dioscorea": 798,
  "Dipeptidyl peptidase 4 (DPP-4) inhibitors": 799,
  "Dipeptidyl peptidase IV (DPP-4) inhibitors": 800,
  "Dipeptidyl peptidase-4 (DPP-4) inhibitors": 801,
  "Direct inhibitors of factor Xa and IIa": 802,
  "Disability": 803,
  "Disorders of glucose metabolism": 804,
  "Disorientation": 805,
  "Distal lower extremity nerve abnormalities": 806,
  "Distal lower limb": 807,
  "Distal nerves of lower limbs": 808,
  "Distal symmetric multiple": 809,
  "Distal symmetric polyneuropathy (DSPN)": 810,
  "Distal symmetrical polyneuropathy": 811,
  "Disturbance of water, electrolyte and acid-base balance": 812,
  "Disuse muscular atrophy of lower limbs": 813,
  "Diuretics": 814,
  "Dizziness": 815,
  "Do aerobic exercise or resistance exercise 2 to 3 times a week": 816,
  "Dobesilic acid": 817,
  "Dominant during pregnancy": 818,
  "Dorsal artery blood flow": 819,
  "Dorsal artery of the foot": 820,
  "Double mitraz": 821,
  "Dried corpse": 822,
  "Drink more": 823,
  "Drink plenty of water": 824,
  "Drug factors such as low-dose aspirin, diuretics, cyclosporine A, mycophenolate mofetil, pyrazinamide, ethambutol": 825,
  "Drug-induced rhabdomyolysis": 826,
  "Drugs that inhibit uric acid production": 827,
  "Drugs that promote uric acid excretion": 828,
  "Dry gangrene": 829,
  "Dry gangrene of the foot or a few toes": 830,
  "Dry skin": 831,
  "Dry skin with poor elasticity": 832,
  "Dual-energy CT": 833,
  "Dulaglutide": 834,
  "Duloxetine": 835,
  "Dyslipidemia": 836,
  "ESRD": 837,
  "Early": 838,
  "Early acute arthritis": 839,
  "Early diabetic nephropathy": 840,
  "Early miscarriage": 841,
  "Early retinopathy": 842,
  "Early stage": 843,
  "Easily taken up via non-receptor pathways": 844,
  "Eat fruits with less fructose, such as cherries, strawberries, pineapples, watermelons, peaches, etc.": 845,
  "Eat more": 846,
  "Edema": 847,
  "Education Management": 848,
  "Education and Administration": 849,
  "Education and psychological intervention": 850,
  "Effect on body weight is neutral or mild": 851,
  "Effective self-management education": 852,
  "Effects on blood sugar": 853,
  "Elbow": 854,
  "Elderly T2DM": 855,
  "Elderly, severe liver and kidney disease": 856,
  "Electrodiagnostic testing": 857,
  "Electrolytes": 858,
  "Electron microscopy and immunofluorescence staining": 859,
  "Elevated liver enzymes": 860,
  "Emotional Management": 861,
  "Emotional Response": 862,
  "Empagliflozin": 863,
  "Empty blood lipids": 864,
  "End stage renal disease (ESRD)": 865,
  "End-stage renal disease": 866,
  "End-stage renal disease (ESRD)": 867,
  "End-stage renal failure": 868,
  "Endogenous creatinine clearance (Ccr)": 869,
  "Endometrial cancer": 870,
  "Endometrium": 871,
  "Endothelial receptor antagonists": 872,
  "Energy-limited meal replacement": 873,
  "Enteral nutrition solution": 874,
  "Especially the Achilles tendon reflex": 875,
  "Estimated glomerular filtration rate (eGFR)": 876,
  "Estradiol (E2)": 877,
  "Etoricoxib": 878,
  "Evening injection": 879,
  "Every 4 hours": 880,
  "Every 4-6 hours": 881,
  "Excessive energy consumption during the peripartum period": 882,
  "Excessive energy intake": 883,
  "Excessive exercise": 884,
  "Excessive fat synthesis": 885,
  "Excessive insulin dose": 886,
  "Excessive production and/or decreased excretion of uric acid": 887,
  "Excessive production of uric acid": 888,
  "Excessive storage of visceral fat": 889,
  "Excessive weight gain": 890,
  "Exenatide": 891,
  "Exenatide weekly preparation": 892,
  "Exercise": 893,
  "Exercise intervention": 894,
  "Exercise regularly": 895,
  "Exercise therapy": 896,
  "Exfoliative dermatitis": 897,
  "Exfoliative skin lesions": 898,
  "Extended release (gliclazide)": 899,
  "Extensive focal myocardial necrosis": 900,
  "Extracellular Matrix (ECM)": 901,
  "Extracellular matrix deposition in the glomerular mesangium": 902,
  "Extracorporeal shock wave lithotripsy": 903,
  "Extremities": 904,
  "Eye": 905,
  "Ezetimibe": 906,
  "FPG": 907,
  "Facial nerve": 908,
  "Fall Injury": 909,
  "Fascia": 910,
  "Fasting TG": 911,
  "Fasting and postprandial TC levels": 912,
  "Fasting and postprandial TG levels": 913,
  "Fasting and postprandial blood sugar": 914,
  "Fasting blood glucose (FPG)": 915,
  "Fasting blood sugar": 916,
  "Fasting high blood sugar": 917,
  "Fasting insulin": 918,
  "Fasting lipid profile": 919,
  "Fasting or postprandial blood sugar": 920,
  "Fasting serum C-peptide level": 921,
  "Fasting serum uric acid": 922,
  "Fasting serum uric acid (SUA)": 923,
  "Fasting serum uric acid level": 924,
  "Fatal and non-fatal": 925,
  "Fatal and nonfatal myocardial infarction": 926,
  "Fatal exfoliative dermatitis": 927,
  "Fatigue": 928,
  "Fatty liver": 929,
  "Fe": 930,
  "Febuxostat": 931,
  "Feed sugar water and milk early": 932,
  "Feeling of cotton wool underfoot when walking": 933,
  "Female serum uric acid": 934,
  "Fenofibrate": 935,
  "Fetal malformation": 936,
  "Fibrates": 937,
  "Fibrinogen": 938,
  "First metatarsal toe": 939,
  "First metatarsophalangeal joint": 940,
  "First-generation sulfonylureas": 941,
  "Fistula": 942,
  "Flexible ureteroscopy": 943,
  "Fluid replacement": 944,
  "Fluid retention": 945,
  "Fluvastatin": 946,
  "Focal asymmetric peripheral neuropathy": 947,
  "Focal asymmetry": 948,
  "Focal tubular atrophy": 949,
  "Folic acid": 950,
  "Follow-up of growth and development": 951,
  "Food intake": 952,
  "Foot": 953,
  "Foot deformity": 954,
  "Foot gangrene": 955,
  "Foot infection": 956,
  "Foot protection": 957,
  "Foot skin ulcers": 958,
  "Foot soft tissue": 959,
  "Foot ulcer": 960,
  "Foot ulcers": 961,
  "Forearm extension": 962,
  "Foreskin of penis": 963,
  "Fosinopril": 964,
  "Foveal thickness": 965,
  "Frequent urination at night": 966,
  "Fructosamine": 967,
  "Frustration": 968,
  "Fufang Xueshuantong Capsule": 969,
  "Fundus examination": 970,
  "Fundus exudation": 971,
  "Fundus fluorescein angiography at 24 weeks": 972,
  "Fundus lesions": 973,
  "Fundus ophthalmoscopy after dilation": 974,
  "Fundus photography": 975,
  "Fundus screening": 976,
  "G1-3": 977,
  "G1~3": 978,
  "G2": 979,
  "G2 and above": 980,
  "G4-5": 981,
  "G4~5": 982,
  "GBM thickening": 983,
  "GDM": 984,
  "GFR": 985,
  "GL-1 receptor agonists": 986,
  "GLP-1": 987,
  "GLP-1 glucose-lowering drugs": 988,
  "GLP-1 receptor agonists": 989,
  "GLP-1RA": 990,
  "GT": 991,
  "Gabapentin": 992,
  "Gaining weight": 993,
  "Gangrene of lower limbs (toes)": 994,
  "Gastric bypass (RYGB)": 995,
  "Gastrointestinal adverse events": 996,
  "Gastrointestinal adverse reactions": 997,
  "Gastrointestinal discomfort": 998,
  "Gastrointestinal disorders": 999,
  "Gastrointestinal effects": 1000,
  "Gastrointestinal perforation": 1001,
  "Gastrointestinal reactions": 1002,
  "Gastrointestinal side effects": 1003,
  "Gastrointestinal surgery": 1004,
  "Gastrointestinal symptoms": 1005,
  "Gastrointestinal, cardiovascular, and renal damage": 1006,
  "Gemfibrozil": 1007,
  "General anesthesia": 1008,
  "Genetic factors": 1009,
  "Genetic susceptibility": 1010,
  "Genetic testing": 1011,
  "Genetics": 1012,
  "Geriatric syndrome": 1013,
  "Gestational diabetes": 1014,
  "Gestational diabetes mellitus (GDM)": 1015,
  "Giant baby": 1016,
  "Ginkgo biloba extract tablets": 1017,
  "Ginkgo biloba preparations": 1018,
  "Glans": 1019,
  "Glibenclamide": 1020,
  "Gliclazide": 1021,
  "Gliclazide extended-release tablets": 1022,
  "Glimaquine": 1023,
  "Glimepiride": 1024,
  "Glipizide": 1025,
  "Glipizide Extended Release Tablets": 1026,
  "Glipizide common dosage form": 1027,
  "Glipizide controlled release": 1028,
  "Gliquidone": 1029,
  "Glitazones": 1030,
  "Glomerular basement membrane thickening": 1031,
  "Glomerular damage": 1032,
  "Glomerular filtration rate": 1033,
  "Glomerular filtration rate (GFR)": 1034,
  "Glomerular lesions": 1035,
  "Glomerular mesangial proliferation": 1036,
  "Glomerulosclerosis": 1037,
  "Glomerulosclerosis (Kelly-Willi syndrome)": 1038,
  "Glomerulus": 1039,
  "Glucagon": 1040,
  "Glucagon-like peptide 1 (GLP-1) receptor agonists": 1041,
  "Glucagon-like peptide 1 analogs": 1042,
  "Glucocorticoids": 1043,
  "Glucose metabolism assessment": 1044,
  "Glucose metabolism status": 1045,
  "Glucose preparations": 1046,
  "Glucose solution": 1047,
  "Glucose tolerance": 1048,
  "Glucose tolerance test": 1049,
  "Glyburide": 1050,
  "Glycated albumin": 1051,
  "Glycated hemoglobin": 1052,
  "Glycated hemoglobin (HbA1c)": 1053,
  "Glycated hemoglobin HbA1c": 1054,
  "Glycated serum albumin": 1055,
  "Glycated serum protein": 1056,
  "Glycemic index": 1057,
  "Glycosidase inhibitors": 1058,
  "Gouty arthritis": 1059,
  "Gouty arthritis interval": 1060,
  "Grade I-II": 1061,
  "Grade III": 1062,
  "Grade III-IV": 1063,
  "Grade III-IV congestive heart failure": 1064,
  "Grade IIb": 1065,
  "Guilt": 1066,
  "HDL cholesterol": 1067,
  "HDL-C": 1068,
  "HDL-C Levels": 1069,
  "HOMA-IR": 1070,
  "HUA": 1071,
  "Half a month": 1072,
  "Halve the recommended dose": 1073,
  "Hard exudate": 1074,
  "HbA1": 1075,
  "HbA1c": 1076,
  "HbA1c Level": 1077,
  "HbH1c": 1078,
  "Headache": 1079,
  "Health Education": 1080,
  "Health Guidance": 1081,
  "Healthy Lifestyle": 1082,
  "Healthy diet": 1083,
  "Healthy eating": 1084,
  "Healthy lifestyle guidance": 1085,
  "Heart": 1086,
  "Heart and kidney function": 1087,
  "Heart and lung diseases": 1088,
  "Heart failure": 1089,
  "Heart function NYHA II~IV": 1090,
  "Heart function NYHA class II~III": 1091,
  "Heart function NYHA class \u2162-\u2163": 1092,
  "Heart function level \u2162-IV": 1093,
  "Heart rate": 1094,
  "Heart rate variability measurement": 1095,
  "Hemodialysis": 1096,
  "Hemolysis": 1097,
  "Hepatic encephalopathy": 1098,
  "Hepatic insufficiency": 1099,
  "Hepatic or renal impairment": 1100,
  "Hepatitis B and C": 1101,
  "Hepatobiliary": 1102,
  "Hepatobiliary diseases": 1103,
  "Hepatotoxicity": 1104,
  "Hidden": 1105,
  "High LDL-C": 1106,
  "High Purity Fish Oil": 1107,
  "High TG levels": 1108,
  "High blood sugar": 1109,
  "High blood sugar levels": 1110,
  "High blood uric acid levels": 1111,
  "High cholesterol": 1112,
  "High protein diet": 1113,
  "High protein intake": 1114,
  "High purity fish oil preparation": 1115,
  "High sugar toxicity": 1116,
  "High uric acid": 1117,
  "High uric acid diet": 1118,
  "High urine pH": 1119,
  "High-density lipoprotein": 1120,
  "High-fiber diet": 1121,
  "High-intensity statins": 1122,
  "High-protein diet": 1123,
  "High-quality low-protein diet": 1124,
  "High-risk foot": 1125,
  "Hirsutism": 1126,
  "Homocysteine (Hcy)": 1127,
  "Homocysteine levels": 1128,
  "Human insulin": 1129,
  "Hyalinization of afferent artery": 1130,
  "Hybrid": 1131,
  "Hydration and alkalinization of urine": 1132,
  "Hydrochlorothiazide": 1133,
  "Hydrolases": 1134,
  "Hydronephrosis": 1135,
  "Hyperalgesia": 1136,
  "Hyperbilirubinemia": 1137,
  "Hypercholesterolemia": 1138,
  "Hypercoagulable state": 1139,
  "Hyperglycemia": 1140,
  "Hyperglycemia during pregnancy": 1141,
  "Hyperglycemia in pregnancy": 1142,
  "Hyperglycemic osmotic diuresis": 1143,
  "Hyperinsulinemia": 1144,
  "Hyperkalemia": 1145,
  "Hyperlipidemia": 1146,
  "Hypersensitivity reactions": 1147,
  "Hypersensitivity syndrome": 1148,
  "Hyperthyroidism": 1149,
  "Hypertonic dehydration": 1150,
  "Hypertonic state": 1151,
  "Hypertonicity": 1152,
  "Hypertriglyceridemia": 1153,
  "Hyperuricemia": 1154,
  "Hypoglycemia": 1155,
  "Hypoglycemia coma": 1156,
  "Hypoglycemia during pregnancy": 1157,
  "Hypoglycemic events": 1158,
  "Hypokalemia": 1159,
  "Hyponatremia": 1160,
  "Hypothyroidism": 1161,
  "Hypoxia": 1162,
  "IDL-C": 1163,
  "IFG": 1164,
  "IGT": 1165,
  "II~IV": 1166,
  "IL-1 receptor antagonists": 1167,
  "IR": 1168,
  "IV push": 1169,
  "IV push or drip": 1170,
  "Idiopathic renal insufficiency": 1171,
  "IgA nephropathy": 1172,
  "Imaging": 1173,
  "Imaging tests": 1174,
  "Immunogenic response": 1175,
  "Immunoglobulin G (IgG)": 1176,
  "Impaired fasting glucose": 1177,
  "Impaired fasting glucose (IFG)": 1178,
  "Impaired glucose regulation (IGR, i.e. prediabetes)": 1179,
  "Impaired glucose tolerance": 1180,
  "Impaired insulin action": 1181,
  "Impaired liver function": 1182,
  "Impaired renal function": 1183,
  "Improper diet control": 1184,
  "Improve microcirculation treatment": 1185,
  "Improve your lifestyle": 1186,
  "Inadequate peripheral blood supply": 1187,
  "Inappropriate dietary restrictions": 1188,
  "Inappropriate exercise": 1189,
  "Inappropriate glucose-lowering therapy": 1190,
  "Increase aerobic exercise": 1191,
  "Increase aerobic exercise (such as brisk walking)": 1192,
  "Increase exercise": 1193,
  "Increase the dose by 500 mg per week": 1194,
  "Increase the special self-care skills needed": 1195,
  "Increased blood sugar": 1196,
  "Increased cardiovascular risk": 1197,
  "Increased carotid intima-media thickness (CIMT)": 1198,
  "Increased fasting blood sugar levels": 1199,
  "Increased frequency of gout attacks": 1200,
  "Increased incidence of gallstones": 1201,
  "Increased life expectancy": 1202,
  "Increased nocturia": 1203,
  "Increased potassium levels": 1204,
  "Increased purulent secretions and necrotic tissue": 1205,
  "Increased risk of falls and fractures": 1206,
  "Increased risk of heart failure": 1207,
  "Increased risk of hypoglycemia": 1208,
  "Increased risk of worsening heart failure and heart failure hospitalization": 1209,
  "Increased visceral fat": 1210,
  "Increased weight or waist circumference": 1211,
  "Incretin drugs": 1212,
  "Indomethacin": 1213,
  "Induce or aggravate heart failure": 1214,
  "Infect": 1215,
  "Infection or ischemia of most or all of the foot": 1216,
  "Infections below the ankle": 1217,
  "Inflammatory factors": 1218,
  "Infrequent menstruation": 1219,
  "Infusion": 1220,
  "Infusion reactions": 1221,
  "Inhalation anesthetics": 1222,
  "Inhibits the excretion of uric acid in the renal tubules": 1223,
  "Inject immediately after a meal": 1224,
  "Inject immediately before meals": 1225,
  "Inject twice a day": 1226,
  "Injection before dinner": 1227,
  "Insomnia": 1228,
  "Instability": 1229,
  "Insufficient insulin levels": 1230,
  "Insufficient insulin secretion": 1231,
  "Insulin": 1232,
  "Insulin Aspart": 1233,
  "Insulin Detemir": 1234,
  "Insulin analogs": 1235,
  "Insulin excretion is reduced in patients with impaired renal function": 1236,
  "Insulin glargine": 1237,
  "Insulin levels": 1238,
  "Insulin lispro": 1239,
  "Insulin may accumulate in the body": 1240,
  "Insulin resistance": 1241,
  "Insulin resistance (IR)": 1242,
  "Insulin resistance + relative insufficiency": 1243,
  "Insulin secretagogue therapy": 1244,
  "Insulin secretagogues": 1245,
  "Insulin secretagogues, glucose-lowering drugs": 1246,
  "Insulin secretion deficiency": 1247,
  "Insulin sensitizers": 1248,
  "Insulin therapy is not standardized": 1249,
  "Intellectual Disability": 1250,
  "Intellectual and physical impairments": 1251,
  "Intermediate- and long-acting insulin": 1252,
  "Intermediate-acting insulin": 1253,
  "Intermittent": 1254,
  "Intermittent claudication": 1255,
  "Intermittent claudication of lower limbs": 1256,
  "Intermittent fasting": 1257,
  "Internal organs": 1258,
  "Interstitial fibrosis": 1259,
  "Intestinal": 1260,
  "Intolerance": 1261,
  "Intra-articular injection": 1262,
  "Intraday blood glucose variability": 1263,
  "Intrapelvic": 1264,
  "Intraretinal cyst": 1265,
  "Intraretinal microvascular abnormality (IRMA)": 1266,
  "Intraspinal": 1267,
  "Intravascular injection": 1268,
  "Intravenous administration": 1269,
  "Intravenous drip": 1270,
  "Intravenous infusion": 1271,
  "Intravenous injection": 1272,
  "Intravenous pump": 1273,
  "Intravenous, intramuscular, or subcutaneous injection": 1274,
  "Iodinated contrast agents": 1275,
  "Irbesartan": 1276,
  "Irregular joint surface": 1277,
  "Ischemia": 1278,
  "Ischemic": 1279,
  "Ischemic cardiovascular and cerebrovascular diseases": 1280,
  "Ischemic cerebral infarction": 1281,
  "Ischemic heart disease": 1282,
  "Ischemic lower extremity arterial disease": 1283,
  "Ischemic stroke": 1284,
  "Ischemic tissue": 1285,
  "Islet cell transplantation": 1286,
  "Islet \u03b2 cell burden": 1287,
  "Isolated hypertriglyceridemia": 1288,
  "Jinlida Granules": 1289,
  "Jinshuibao": 1290,
  "Job's tears": 1291,
  "Joint Ultrasound": 1292,
  "Joint cavity": 1293,
  "Joint disease": 1294,
  "Joint fluid microbial culture": 1295,
  "Joint space narrowing": 1296,
  "K-W (Kimmelstiel-Wilson) nodules": 1297,
  "Kallikrein": 1298,
  "Keep exercising": 1299,
  "Keep your bladder open": 1300,
  "Ketone bodies": 1301,
  "Ketonemia": 1302,
  "Ketosis": 1303,
  "Kidney Nephropathy": 1304,
  "Kidney damage": 1305,
  "Kidney dialysis": 1306,
  "Kidney disease": 1307,
  "Kidney failure": 1308,
  "Kidney hypertrophy": 1309,
  "Kidney injury molecule 1 (Kim-1)": 1310,
  "Kidney stones": 1311,
  "Kidney transplant": 1312,
  "Kidney ultrasound": 1313,
  "Kidney xanthine and hypoxanthine stones": 1314,
  "Knotweed": 1315,
  "Knuckles": 1316,
  "LDL cholesterol": 1317,
  "LDL cholesterol levels": 1318,
  "LDL-C": 1319,
  "LDL-C levels": 1320,
  "LEAD": 1321,
  "Labetalol": 1322,
  "Lactic acid": 1323,
  "Lactic acidosis": 1324,
  "Laparoscopic sleeve gastrectomy (LSG)": 1325,
  "Large abscess": 1326,
  "Large blood vessels": 1327,
  "Large vessel atherosclerosis": 1328,
  "Large vessel atherosclerotic plaque": 1329,
  "Large vessel disease": 1330,
  "Large vessel sclerosis": 1331,
  "Laser photocoagulation": 1332,
  "Laser photocoagulation therapy": 1333,
  "Laser therapy": 1334,
  "Late stage": 1335,
  "Late \u03b2-cell failure": 1336,
  "Latent diabetes": 1337,
  "Length-dependent axonal": 1338,
  "Length-dependent axonal neuropathy": 1339,
  "Less bleeding from wound": 1340,
  "Less movement": 1341,
  "Less than 50 U/d": 1342,
  "Less than 50 units/day": 1343,
  "Level I": 1344,
  "Level II and above": 1345,
  "Level II to III": 1346,
  "Level II to IV": 1347,
  "Level III-IV": 1348,
  "Level III~IV": 1349,
  "Level IV": 1350,
  "Level l-II": 1351,
  "Life-threatening": 1352,
  "Lifestyle behavior intervention": 1353,
  "Lifestyle changes": 1354,
  "Lifestyle intervention": 1355,
  "Lifestyle interventions": 1356,
  "Limb ischemia": 1357,
  "Limb muscle weakness": 1358,
  "Limb numbness": 1359,
  "Limb ulcers": 1360,
  "Limbs": 1361,
  "Limit alcohol intake": 1362,
  "Limit sodium intake": 1363,
  "Limited mobility": 1364,
  "Linagliptin": 1365,
  "Lipid levels": 1366,
  "Lipid metabolism disorders": 1367,
  "Lipid parameters": 1368,
  "Lipid profile": 1369,
  "Lipid regulation": 1370,
  "Lipid-lowering drugs": 1371,
  "Lipomicrosphere alprostadil injection": 1372,
  "Liraglutide": 1373,
  "Lisinopril": 1374,
  "Liver and Kidney": 1375,
  "Liver and kidney damage": 1376,
  "Liver and kidney diseases": 1377,
  "Liver and kidney dysfunction": 1378,
  "Liver and kidney function": 1379,
  "Liver damage": 1380,
  "Liver disease": 1381,
  "Liver dysfunction": 1382,
  "Liver enzymes": 1383,
  "Liver failure": 1384,
  "Liver function": 1385,
  "Liver function tests": 1386,
  "Liver inflammation": 1387,
  "Liver ultrasound": 1388,
  "Liver, kidney, heart and lung dysfunction": 1389,
  "Lixisenatide": 1390,
  "Local blood supply disorder": 1391,
  "Local blood supply disorder of extremities": 1392,
  "Local skin peeling": 1393,
  "Loneliness": 1394,
  "Long-acting calcium channel blockers": 1395,
  "Long-acting calcium channel blockers (CCBs)": 1396,
  "Long-acting insulin": 1397,
  "Long-acting insulin analogs": 1398,
  "Long-term dressing": 1399,
  "Long-term regular exercise": 1400,
  "Loop diuretics": 1401,
  "Losartan": 1402,
  "Lose 5% to 10% of your body weight": 1403,
  "Lose weight": 1404,
  "Loss of appetite": 1405,
  "Loss of sensation": 1406,
  "Low back pain": 1407,
  "Low blood": 1408,
  "Low blood pressure": 1409,
  "Low distal amputation": 1410,
  "Low energy diet": 1411,
  "Low fat": 1412,
  "Low molecular weight heparin": 1413,
  "Low specific gravity urine": 1414,
  "Low-density lipoprotein": 1415,
  "Low-density lipoprotein cholesterol (LDL-C) can also act on LDL receptors on glomerular mesangial cells": 1416,
  "Low-protein diet": 1417,
  "Low-protein diet therapy": 1418,
  "Low-salt diet": 1419,
  "Lower calyx stones": 1420,
  "Lower extremity arterial calcification": 1421,
  "Lower extremity arterial disease": 1422,
  "Lower extremity arterial occlusive disease": 1423,
  "Lower extremity arterial stenosis": 1424,
  "Lower extremity artery occlusion": 1425,
  "Lower extremity atherosclerotic disease (LEAD)": 1426,
  "Lower extremity vascular disease": 1427,
  "Lower limb arterial ischemia": 1428,
  "Lower limb arteries": 1429,
  "Lower limb artery": 1430,
  "Lower limb blood vessels": 1431,
  "Lower limb ischemia": 1432,
  "Lower limb ischemia (CLI)": 1433,
  "Lower limb lesions": 1434,
  "Lower limb skin": 1435,
  "Lower limbs": 1436,
  "Lower renal calyx": 1437,
  "Lower stone": 1438,
  "Lowering blood uric acid concentration": 1439,
  "Lowers blood pressure": 1440,
  "Lumbar plexus": 1441,
  "Lumbar plexus disease": 1442,
  "Lumbar sacral nerve root plexus distribution": 1443,
  "Lumen stenosis or occlusion": 1444,
  "Lung cancer": 1445,
  "Lung infection": 1446,
  "Lungs": 1447,
  "Luseogliflozin": 1448,
  "Lymphangitis": 1449,
  "Lymphatic vessels": 1450,
  "MDI": 1451,
  "MODY Gene Testing": 1452,
  "MS": 1453,
  "Macrovascular and microvascular diseases": 1454,
  "Macrovascular and microvascular events": 1455,
  "Macrovascular complications": 1456,
  "Macrovascular complications of diabetes": 1457,
  "Macrovascular events": 1458,
  "Macula": 1459,
  "Macular degeneration": 1460,
  "Macular edema": 1461,
  "Magnetic resonance angiography (MRA)": 1462,
  "Magnetic resonance imaging of liver fat": 1463,
  "Mainly ischemic changes": 1464,
  "Male serum uric acid": 1465,
  "Malignant": 1466,
  "Malignant middle cerebral artery infarction": 1467,
  "Malignant tumor with metastasis": 1468,
  "Malignant tumors": 1469,
  "Maturity-onset diabetes of the young (MODY)": 1470,
  "Mealtime insulin": 1471,
  "Median nerve": 1472,
  "Medical Nutrition Therapy (MNT)": 1473,
  "Mediterranean diet": 1474,
  "Medium- and long-acting sulfonylurea secretagogues": 1475,
  "Medullary thyroid cancer (MTC)": 1476,
  "Megaloblastic anemia": 1477,
  "Meglitinides": 1478,
  "Meglitinides oral hypoglycemic drugs": 1479,
  "Menopause": 1480,
  "Mental Health Counseling": 1481,
  "Mental or intellectual disability": 1482,
  "Mental stress": 1483,
  "Metabolic": 1484,
  "Metabolic abnormalities": 1485,
  "Metabolic complications": 1486,
  "Metabolic disorders": 1487,
  "Metabolic instability": 1488,
  "Metabolic surgery": 1489,
  "Metabolic syndrome": 1490,
  "Metalloproteinase 9": 1491,
  "Metformin": 1492,
  "Metformin Hydrochloride": 1493,
  "Methyl B12": 1494,
  "Methylcobalamin": 1495,
  "Metoprolol": 1496,
  "Micro-obstacles": 1497,
  "Microalbumin": 1498,
  "Microalbumin/creatinine ratio (UACR)": 1499,
  "Microalbuminuria": 1500,
  "Microaneurysm": 1501,
  "Microangiopathy": 1502,
  "Microcirculatory disorders": 1503,
  "Microvascular": 1504,
  "Microvascular and macrovascular diseases": 1505,
  "Microvascular circulatory disorder": 1506,
  "Microvascular complications": 1507,
  "Microvascular events": 1508,
  "Middle cerebral artery": 1509,
  "Miglitol": 1510,
  "Mild": 1511,
  "Mild cognitive impairment": 1512,
  "Mild hypoglycemia": 1513,
  "Mild mesangial hyperplasia": 1514,
  "Mild nausea": 1515,
  "Mild to moderate": 1516,
  "Mild to moderate hypoglycemia": 1517,
  "Mild to moderate liver impairment": 1518,
  "Mild to moderate renal dysfunction": 1519,
  "Mild to moderate renal insufficiency": 1520,
  "Minimally invasive endovascular treatment (balloon dilatation and stent implantation)": 1521,
  "Mixed": 1522,
  "Mixed dyslipidemia": 1523,
  "Moderate": 1524,
  "Moderate (grade 3b) and severe": 1525,
  "Moderate (grade 3b) and severe renal failure": 1526,
  "Moderate indoor activities after meals": 1527,
  "Moderate renal insufficiency": 1528,
  "Moderate to severe": 1529,
  "Moderate to severe chronic kidney disease": 1530,
  "Moderate to severe cognitive impairment": 1531,
  "Moderate to severe renal insufficiency": 1532,
  "Moderate-intensity statins": 1533,
  "Moderate-strength statins": 1534,
  "Monitor renal function 2 to 4 times": 1535,
  "Monitoring PPG": 1536,
  "Monitoring blood uric acid levels": 1537,
  "Monitoring renal function": 1538,
  "Mononeuropathy": 1539,
  "Mood disorders": 1540,
  "More significant weight gain": 1541,
  "More than 24 hours": 1542,
  "More than one tuberous sclerosis (K-W nodule)": 1543,
  "Motor nerve": 1544,
  "Motor nerve axonal damage": 1545,
  "Multiple coexisting diseases": 1546,
  "Multiple daily subcutaneous insulin injections (MDI)": 1547,
  "Multiple endocrine neoplasia syndrome type 2": 1548,
  "Multiple mononeuropathy": 1549,
  "Multiple symmetrical peripheral neuropathy": 1550,
  "Multiple symmetry": 1551,
  "Multiple times a day": 1552,
  "Muscle atrophy": 1553,
  "Muscle damage": 1554,
  "Muscle discomfort": 1555,
  "Muscle tenderness": 1556,
  "Muscle tissue": 1557,
  "Muscle tissue sandwich necrosis": 1558,
  "Muscular atrophy": 1559,
  "Myeloproliferative disorders": 1560,
  "Myocardial infarction": 1561,
  "Myocardial ischemia": 1562,
  "Myocardium": 1563,
  "Myoenzyme": 1564,
  "Myopathy": 1565,
  "Myositis": 1566,
  "Myotoxicity": 1567,
  "NAFLD": 1568,
  "NASH": 1569,
  "NCV": 1570,
  "NGAL": 1571,
  "NPDR": 1572,
  "NPH": 1573,
  "NSAIDs": 1574,
  "NYHA heart function class II~IV": 1575,
  "Nasopharyngitis": 1576,
  "Nateglinide": 1577,
  "Necrobiosis lipoidica": 1578,
  "Necrotic limb infection": 1579,
  "Necrotizing fasciitis": 1580,
  "Needle electrode detection": 1581,
  "Needle electromyography": 1582,
  "Needle prick pain": 1583,
  "Needle-like pain": 1584,
  "Negative nutritional balance": 1585,
  "Neovascular glaucoma": 1586,
  "Neovascularization of the retina or optic disc": 1587,
  "Nephrolithiasis": 1588,
  "Nephrotic syndrome": 1589,
  "Nephrotoxic drugs": 1590,
  "Nerve Growth Factor": 1591,
  "Nerve biopsy": 1592,
  "Nerve conduction dysfunction": 1593,
  "Nerve conduction studies": 1594,
  "Nerve conduction velocity (NCV)": 1595,
  "Nerve plexus": 1596,
  "Nerve root compression": 1597,
  "Nerve root or plexus": 1598,
  "Nerve root or plexus disease": 1599,
  "Nerve root peripheral nerve": 1600,
  "Nerve roots": 1601,
  "Neuralgia": 1602,
  "Neurodegenerative diseases": 1603,
  "Neuroelectrophysiologic examination": 1604,
  "Neuroischemic type (also called mixed type)": 1605,
  "Neurological disorders": 1606,
  "Neuropathic arthropathy (Charcot arthropathy)": 1607,
  "Neuropathic ulcers": 1608,
  "Neuropathy": 1609,
  "Neurophysiology": 1610,
  "Neuroretinal abnormalities": 1611,
  "Neurotic": 1612,
  "Neutral protamine zinc insulin": 1613,
  "Neutrophil gelatinase": 1614,
  "New York Heart Association (NYHA) heart function class II or above": 1615,
  "New-onset diabetes": 1616,
  "Next": 1617,
  "Niacin drugs": 1618,
  "Niacin preparations": 1619,
  "Nifedipine": 1620,
  "Nighttime blood sugar": 1621,
  "No perception of hypoglycemia": 1622,
  "No sweat": 1623,
  "No yellow wine, beer or liquor": 1624,
  "Nocturnal hypoxia": 1625,
  "Non-HDL-C": 1626,
  "Non-alcoholic fatty": 1627,
  "Non-dihydropyridine CCBs": 1628,
  "Non-dihydropyridine calcium antagonists": 1629,
  "Non-enzymatic glycation of proteins": 1630,
  "Non-fatal myocardial infarction": 1631,
  "Non-insulin injections": 1632,
  "Non-insulin secretagogue oral glucose-lowering drugs": 1633,
  "Non-insulin secretagogues": 1634,
  "Non-lethal": 1635,
  "Non-mydriatic fundus camera": 1636,
  "Non-mydriatic fundus photography": 1637,
  "Non-narcotic analgesics": 1638,
  "Non-proliferative": 1639,
  "Non-proliferative diabetic retinopathy (NPDR)": 1640,
  "Non-proliferative phase": 1641,
  "Non-sulfonylurea insulin secretagogues": 1642,
  "Non-thiazide diuretics": 1643,
  "Non-traumatic low amputation": 1644,
  "Nonalcoholic fatty liver disease": 1645,
  "Nonalcoholic fatty liver disease (NAFLD)": 1646,
  "Nonalcoholic steatohepatitis": 1647,
  "Nonalcoholic steatohepatitis (NASH)": 1648,
  "Nonfatal ischemic stroke": 1649,
  "Nonfatal myocardial infarction": 1650,
  "Nonfatal stroke": 1651,
  "Nonproliferative diabetic retinopathy": 1652,
  "Nonselective COX inhibitors": 1653,
  "Nonsteroidal anti-inflammatory drugs": 1654,
  "Nonsteroidal anti-inflammatory drugs (NSAIDs)": 1655,
  "Normal protein diet": 1656,
  "Normal saline": 1657,
  "Normal, mild, moderate, severe, and extremely severe renal impairment": 1658,
  "Normoalbuminuria": 1659,
  "Not more than 10 mg": 1660,
  "Number of small, dense LDL particles": 1661,
  "Numbness in the foot": 1662,
  "Nutrition Education": 1663,
  "Nutrition and exercise guidance": 1664,
  "Nutritional therapy": 1665,
  "OGTT": 1666,
  "OSAHS": 1667,
  "Obesity": 1668,
  "Obesity due to loss of muscle mass": 1669,
  "Oliguria": 1670,
  "Omentum": 1671,
  "Once a day": 1672,
  "Once a day (qd)": 1673,
  "Once a week": 1674,
  "One-quarter of the recommended amount": 1675,
  "Onychomycosis": 1676,
  "Oral contraceptives": 1677,
  "Oral glucose (75 g) tolerance test (OGTT)": 1678,
  "Oral glucose tolerance test (OGTT)": 1679,
  "Oral or dental problems": 1680,
  "Organ damage": 1681,
  "Organ dysfunction": 1682,
  "Organ transplantation": 1683,
  "Organs": 1684,
  "Orthostatic hypotension": 1685,
  "Osmotic diuresis": 1686,
  "Osteoarthritis may occur at the edge of the bone": 1687,
  "Osteofascial compartment": 1688,
  "Osteoporosis": 1689,
  "Ovaries": 1690,
  "Overdosage": 1691,
  "Overt diabetes mellitus during pregnancy": 1692,
  "Oxidative stress": 1693,
  "PCOS": 1694,
  "PCSK9 inhibitors": 1695,
  "PDR": 1696,
  "PGDM": 1697,
  "PGE1": 1698,
  "PPG": 1699,
  "Pain": 1700,
  "Pain on exertion": 1701,
  "Painful": 1702,
  "Painful neuropathy": 1703,
  "Painful peripheral neuropathy": 1704,
  "Palpitations": 1705,
  "Panax notoginseng preparations": 1706,
  "Pancreatic Islets": 1707,
  "Pancreatic beta cell function is very poor": 1708,
  "Pancreatic beta cells can further deteriorate": 1709,
  "Pancreatic cancer": 1710,
  "Pancreatic \u03b2-cell dysfunction": 1711,
  "Pancreatic \u03b2-cell function continues to deteriorate as the disease progresses": 1712,
  "Pancreatic \u03b2-cell function gradually deteriorates as the disease progresses": 1713,
  "Pancreatic \u03b2-cell function has been significantly impaired": 1714,
  "Paresthesias": 1715,
  "Parkinson's disease": 1716,
  "Passive smoking": 1717,
  "Patients with T2DM": 1718,
  "Patients with impaired liver and kidney function": 1719,
  "Patients with multiple endocrine neoplasia type 2 (MEN2)": 1720,
  "Patients with type 2 diabetes": 1721,
  "Pay attention to diet and exercise": 1722,
  "Pay attention to personal genital hygiene": 1723,
  "Pelvic space-occupying lesions": 1724,
  "Pentoxifylline": 1725,
  "People with heart failure": 1726,
  "Peptic ulcer": 1727,
  "Pericyte loss": 1728,
  "Perindopril": 1729,
  "Perioperative Hyperglycemia": 1730,
  "Perioperative blood sugar": 1731,
  "Perioperative period": 1732,
  "Peripheral Arterial Disease (PAD)": 1733,
  "Peripheral arterial disease": 1734,
  "Peripheral arteries": 1735,
  "Peripheral blood vessels": 1736,
  "Peripheral insulin resistance": 1737,
  "Peripheral nerves": 1738,
  "Peripheral neuropathy": 1739,
  "Peripheral neuropathy (DPN)": 1740,
  "Peripheral vascular disease": 1741,
  "Peritoneal dialysis": 1742,
  "Persistent HUA sodium urate crystals deposited in the renal medullary interstitial tissue": 1743,
  "Persistent hyperglycemia": 1744,
  "Phallitis": 1745,
  "Phase 1~2": 1746,
  "Phase 1~3": 1747,
  "Phase 3": 1748,
  "Phase 3 and 4": 1749,
  "Phase 3a": 1750,
  "Phase 3b": 1751,
  "Phase 3b~4": 1752,
  "Phase 3b~5": 1753,
  "Phase 3~4": 1754,
  "Phase I~2": 1755,
  "Phenoxy aromatic acids": 1756,
  "Physical activity": 1757,
  "Physical activity (200-300 minutes per week)": 1758,
  "Physical activity (eg, 200 to 300 minutes per week)": 1759,
  "Physical examination": 1760,
  "Physical exercise": 1761,
  "Physical exercise 3 to 4 times a week": 1762,
  "Pigmentation": 1763,
  "Pinprick sensation": 1764,
  "Pioglitazone": 1765,
  "Pipe blocking": 1766,
  "Pitavastatin": 1767,
  "Placebo": 1768,
  "Plasma TG": 1769,
  "Plasma aldosterone": 1770,
  "Plasma aldosterone level": 1771,
  "Plasma concentration": 1772,
  "Plasma glucose testing": 1773,
  "Plasma insulin": 1774,
  "Plasma proteins": 1775,
  "Platelet aggregation": 1776,
  "Podiatry": 1777,
  "Point-like strong echoes and strong echo groups in joints with acoustic shadows": 1778,
  "Polycystic Ovary Syndrome (PCOS)": 1779,
  "Polycystic kidney disease": 1780,
  "Polycystic ovary": 1781,
  "Polycystic ovary syndrome": 1782,
  "Polyol pathway activation": 1783,
  "Polyuria": 1784,
  "Poorer insulin secretion": 1785,
  "Possible decrease in white blood cells, red blood cells, and eosinophils": 1786,
  "Post-meal exercise": 1787,
  "Post-meal peak": 1788,
  "Posterior vitreous penetration ratio (PVPR)": 1789,
  "Postoperative follow-up": 1790,
  "Postprandial blood glucose (PPG)": 1791,
  "Postprandial blood sugar": 1792,
  "Postprandial blood sugar increase": 1793,
  "Postprandial peak blood sugar": 1794,
  "Potassium Sodium Hydrogen Citrate": 1795,
  "Potassium Sodium Hydrogen Citrate Granules": 1796,
  "Potassium level": 1797,
  "Potassium moves into cells": 1798,
  "Pravastatin": 1799,
  "Pre-gestational diabetes": 1800,
  "Pre-meal blood sugar": 1801,
  "Pre-pregnancy type 2 diabetes": 1802,
  "Prediabetes": 1803,
  "Prediabetic peripheral neuropathy": 1804,
  "Prednisolone": 1805,
  "Prednisone": 1806,
  "Pregabalin": 1807,
  "Pregnancy": 1808,
  "Prekashi": 1809,
  "Premature ischemic cardiovascular disease": 1810,
  "Premixed human insulin": 1811,
  "Premixed insulin": 1812,
  "Premixed insulin analogs": 1813,
  "Preretinal hemorrhage": 1814,
  "Pressure sensation": 1815,
  "Pretibial pigmentation": 1816,
  "Probenecid": 1817,
  "Progressive decline in pancreatic \u03b2-cell function": 1818,
  "Progressive decline in renal function": 1819,
  "Proliferative": 1820,
  "Proliferative diabetic retinopathy (PDR)": 1821,
  "Prolonged fasting": 1822,
  "Promote the generation of oxygen free radicals": 1823,
  "Prostaglandin E1 preparations": 1824,
  "Prostate cancer": 1825,
  "Protein kinase C activation": 1826,
  "Proteinuria": 1827,
  "Provide emotional support": 1828,
  "Providing emotional support related to depression": 1829,
  "Pseudarthrosis": 1830,
  "Psychological interventions": 1831,
  "Psychological support": 1832,
  "Pump": 1833,
  "Purinol": 1834,
  "Pyridorin": 1835,
  "Quantitative sensory testing": 1836,
  "Quit or reduce smoking": 1837,
  "Quit smoking and limit alcohol consumption": 1838,
  "Quitting smoking": 1839,
  "Radiation therapy": 1840,
  "Raised LDL-C": 1841,
  "Ramipril": 1842,
  "Random blood sugar": 1843,
  "Random or 2hPG": 1844,
  "Ranibizumab": 1845,
  "Rapid failure of pancreatic \u03b2-cell function": 1846,
  "Rapid-acting insulin": 1847,
  "Rapid-acting insulin analogs": 1848,
  "Rasburicase": 1849,
  "Rear cable damage": 1850,
  "Receive food support and education": 1851,
  "Recognized and engulfed by scavenger receptors of monocytes and macrophages to form foam cells": 1852,
  "Rectal cancer": 1853,
  "Recurrent peptic ulcer/bleeding": 1854,
  "Redness, swelling, heat, and pain in single joints such as the first metatarsal toe, ankle, and knee": 1855,
  "Reduce patient weight": 1856,
  "Reduce proteinuria": 1857,
  "Reduce your weight": 1858,
  "Reduced excretion": 1859,
  "Reduced foot temperature": 1860,
  "Reduction of 30%-50%": 1861,
  "Refractory acute gout": 1862,
  "Refractory gout": 1863,
  "Refractory gout in adults": 1864,
  "Refractory infection": 1865,
  "Regional anesthesia": 1866,
  "Regular breakfast": 1867,
  "Regular exercise": 1868,
  "Regular insulin": 1869,
  "Relatively increased glucagon secretion": 1870,
  "Relatively insufficient insulin secretion": 1871,
  "Relaxation practice": 1872,
  "Renal": 1873,
  "Renal adverse events": 1874,
  "Renal artery": 1875,
  "Renal artery stenosis": 1876,
  "Renal biopsy": 1877,
  "Renal blood vessels": 1878,
  "Renal calyx": 1879,
  "Renal degradation of insulin is significantly reduced": 1880,
  "Renal events": 1881,
  "Renal failure": 1882,
  "Renal function": 1883,
  "Renal function decline": 1884,
  "Renal glucose threshold": 1885,
  "Renal impairment": 1886,
  "Renal impairment \u2265 G2": 1887,
  "Renal insufficiency": 1888,
  "Renal interstitial fibrosis": 1889,
  "Renal interstitium": 1890,
  "Renal microvascular sclerosis": 1891,
  "Renal microvessels": 1892,
  "Renal or hepatic impairment": 1893,
  "Renal osteodystrophy": 1894,
  "Renal parenchyma": 1895,
  "Renal parenchymal atrophy": 1896,
  "Renal pathology examination": 1897,
  "Renal pelvic stones": 1898,
  "Renal pelvis": 1899,
  "Renal puncture": 1900,
  "Renal replacement therapy": 1901,
  "Renal tissue light microscopy": 1902,
  "Renal tubular damage": 1903,
  "Renal tubular/renal vascular damage": 1904,
  "Renal tubules": 1905,
  "Renal vascular injury": 1906,
  "Renin angiotensin system (RAS) inhibitors": 1907,
  "Renin inhibitors": 1908,
  "Reocclusion": 1909,
  "Repaglinide": 1910,
  "Repeat blood pressure test 3 times": 1911,
  "Reproduction": 1912,
  "Reproductive and urinary tract infections": 1913,
  "Reproductive tract": 1914,
  "Reproductive tract infections": 1915,
  "Resistance training": 1916,
  "Resistant hypertension": 1917,
  "Rest pain": 1918,
  "Restenosis": 1919,
  "Resting pain in limbs": 1920,
  "Resting tachycardia": 1921,
  "Retina": 1922,
  "Retinal hemorrhage": 1923,
  "Retinal laser treatment": 1924,
  "Retinal neovascular disease": 1925,
  "Retinal neovascularization": 1926,
  "Retinal photocoagulation therapy": 1927,
  "Retinal vein occlusion": 1928,
  "Retinopathy": 1929,
  "Rhabdomyolysis": 1930,
  "Rhein": 1931,
  "Rosiglitazone": 1932,
  "Rosuvastatin": 1933,
  "Rupture": 1934,
  "S GLT-2 inhibitors": 1935,
  "S Us": 1936,
  "SCr": 1937,
  "SGLT-2 inhibitors": 1938,
  "SGLT2 inhibitors": 1939,
  "SGLT2i": 1940,
  "SMBG": 1941,
  "SUA": 1942,
  "Sarcopenia": 1943,
  "Sarpogrelate hydrochloride": 1944,
  "Saxagliptin": 1945,
  "Schwann cell proliferation": 1946,
  "Scleredema": 1947,
  "Screening for complications": 1948,
  "Screening or evaluation for chronic complications": 1949,
  "Se": 1950,
  "Second-generation sulfonylureas": 1951,
  "Secondary": 1952,
  "Secondary HUA": 1953,
  "Secondary gout": 1954,
  "Secondary hyperuricemia": 1955,
  "Secretagogues": 1956,
  "Selective PPAR-\u03b3 (peroxisome proliferator-activated receptor-gamma) receptor agonist": 1957,
  "Selective beta-blockers": 1958,
  "Selective cholesterol absorption inhibitors": 1959,
  "Selective cyclooxygenase 2 (COX-2) inhibitors": 1960,
  "Self-Care": 1961,
  "Self-management": 1962,
  "Self-management support": 1963,
  "Self-monitoring of blood glucose (SMBG)": 1964,
  "Sensory ataxia": 1965,
  "Sensory examination": 1966,
  "Sensory impairment": 1967,
  "Sensory impairment in the lower limbs": 1968,
  "Sensory nerve action potential": 1969,
  "Sensory nerve conduction studies": 1970,
  "Sensory nerve conduction velocity": 1971,
  "Sensory nerves": 1972,
  "Seratate hydrochloride": 1973,
  "Serious cardiovascular events": 1974,
  "Serum Cu": 1975,
  "Serum LDL-C": 1976,
  "Serum Protein": 1977,
  "Serum TG": 1978,
  "Serum creatinine": 1979,
  "Serum creatinine (SCr)": 1980,
  "Serum creatinine level": 1981,
  "Serum enzymology": 1982,
  "Serum lactate": 1983,
  "Serum potassium": 1984,
  "Serum testosterone": 1985,
  "Serum total cholesterol and low-density lipoprotein cholesterol levels": 1986,
  "Serum transaminase": 1987,
  "Serum transaminases": 1988,
  "Serum uric acid": 1989,
  "Serum uric acid (SUA)": 1990,
  "Serum vitamin B12": 1991,
  "Severe": 1992,
  "Severe allergic reactions": 1993,
  "Severe arrhythmia": 1994,
  "Severe cardiovascular and cerebrovascular diseases": 1995,
  "Severe gastrointestinal reactions": 1996,
  "Severe heart failure": 1997,
  "Severe hyperglycemia (>16.7mmol/L": 1998,
  "Severe hypersensitivity reactions": 1999,
  "Severe hypoglycemia": 2000,
  "Severe hypoglycemic events": 2001,
  "Severe infection": 2002,
  "Severe liver damage": 2003,
  "Severe liver dysfunction": 2004,
  "Severe liver or kidney damage": 2005,
  "Severe mesangial proliferation": 2006,
  "Severe pancreatic disease": 2007,
  "Severe renal impairment": 2008,
  "Severe renal insufficiency": 2009,
  "Severe skin adverse reactions": 2010,
  "Severe vitreous thickening": 2011,
  "Severe wet or dry gangrene or necrosis of the feet or toes": 2012,
  "Sex hormone-binding globulin": 2013,
  "Sexual dysfunction": 2014,
  "Short-acting glucagon-like peptide-1 (GLP-1) receptor agonists": 2015,
  "Short-acting glucocorticoids": 2016,
  "Short-acting human insulin": 2017,
  "Short-acting insulin": 2018,
  "Short-acting or rapid-acting insulin": 2019,
  "Short-acting secretagogues": 2020,
  "Short-acting sulfonylurea secretagogues": 2021,
  "Short-acting sulfonylureas": 2022,
  "Short-acting/rapid-acting insulin": 2023,
  "Shortened red blood cell lifespan": 2024,
  "Significant differences in responses to the three major macronutrients (carbohydrates, protein, and fat)": 2025,
  "Significant limb weakness": 2026,
  "Significant weight gain": 2027,
  "Simple diet control": 2028,
  "Simple ischemic ulcer": 2029,
  "Simple neurological type": 2030,
  "Simple type": 2031,
  "Simvastatin": 2032,
  "Single joint": 2033,
  "Single or intermittent": 2034,
  "Sitagliptin": 2035,
  "Skin adverse reactions": 2036,
  "Skin biopsy": 2037,
  "Skin complications of diabetes": 2038,
  "Skin damage": 2039,
  "Skin damage on the limbs": 2040,
  "Skin dystrophy": 2041,
  "Skin flap transplantation": 2042,
  "Skin infections": 2043,
  "Skin lesions": 2044,
  "Skin rash": 2045,
  "Small Fiber": 2046,
  "Small amount": 2047,
  "Small and dense LDL particles are more susceptible to oxidation to form lipid peroxides": 2048,
  "Small fiber nerves": 2049,
  "Small fiber neuropathy": 2050,
  "Small molecule protein": 2051,
  "Small, dense LDL particles": 2052,
  "Smilax": 2053,
  "Smilax glabra": 2054,
  "Smoking": 2055,
  "Social support": 2056,
  "Sodium bicarbonate": 2057,
  "Sodium bicarbonate (baking soda)": 2058,
  "Sodium urate crystals deposited in joints and other tissues": 2059,
  "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors": 2060,
  "Sodium-glucose co-transporter 2 inhibitors": 2061,
  "Sodium-glucose co-transporter 2 inhibitors (SGLT2i)": 2062,
  "Soft tissue": 2063,
  "Soft tissue and bone destruction": 2064,
  "Soft tissue swelling": 2065,
  "Spinal canal": 2066,
  "Spinal cord lesions": 2067,
  "Spinal stenosis": 2068,
  "Spine and spinal canal lesions": 2069,
  "Spironolactone": 2070,
  "Sports Management": 2071,
  "Sports rehabilitation exercises": 2072,
  "Stable period": 2073,
  "Stage 1~3a": 2074,
  "Statins": 2075,
  "Steatosis and fibrosis": 2076,
  "Stem Cell Therapy": 2077,
  "Stem cell transplantation": 2078,
  "Stenosis of the coronary arteries, carotid arteries, or lower limb arteries": 2079,
  "Steroid-induced": 2080,
  "Stevens-Johnson syndrome": 2081,
  "Stocking-like changes": 2082,
  "Stomach": 2083,
  "Stomach bloating": 2084,
  "Stone formation": 2085,
  "Stone removal therapy": 2086,
  "Stop drinking": 2087,
  "Straight heart tube": 2088,
  "Strengthen psychological intervention": 2089,
  "Strengthen your exercise": 2090,
  "Stress": 2091,
  "Stress during labor and before and after surgery": 2092,
  "Stress-induced hyperglycemia": 2093,
  "Stroke": 2094,
  "Stubbornness": 2095,
  "Subclinical": 2096,
  "Subclinical peripheral neuropathy": 2097,
  "Subcutaneous": 2098,
  "Subcutaneous injection": 2099,
  "Subcutaneous injection 15-30 minutes before meals": 2100,
  "Subcutaneous injection 30 minutes before breakfast and dinner": 2101,
  "Subcutaneous injection 30 minutes before meals": 2102,
  "Subcutaneous injection immediately before meals": 2103,
  "Subcutaneous insulin injection": 2104,
  "Sudden abnormal behavior": 2105,
  "Sudden behavioral changes": 2106,
  "Sudden cold": 2107,
  "Sugar (g): Insulin (U)": 2108,
  "Sugar macular edema": 2109,
  "Sugary liquids": 2110,
  "Sugary nutrient solution": 2111,
  "Sulfonylurea insulin secretagogues": 2112,
  "Sulfonylurea secretagogues": 2113,
  "Sulfonylureas": 2114,
  "Sulfonylureas (SUs)": 2115,
  "Sulodex": 2116,
  "Suprarenal calyx": 2117,
  "Symptomatic hypoglycemia": 2118,
  "Synchronous ischemic vascular lesions in both lower limbs": 2119,
  "Systemic arteries": 2120,
  "Systemic atherosclerotic changes": 2121,
  "Systemic atherosclerotic disease": 2122,
  "Systole": 2123,
  "Systolic blood pressure": 2124,
  "Systolic hypertension": 2125,
  "T1": 2126,
  "T1DM": 2127,
  "T2": 2128,
  "T2DDM": 2129,
  "T2DM": 2130,
  "TC": 2131,
  "TG": 2132,
  "TG drugs": 2133,
  "TG levels": 2134,
  "TG-lowering drugs": 2135,
  "TLC": 2136,
  "TZD": 2137,
  "Take 1 to 2 times a day": 2138,
  "Take before meals": 2139,
  "Take once a day": 2140,
  "Take with or after meals": 2141,
  "Take with or immediately after a meal": 2142,
  "Take with or immediately after dinner": 2143,
  "Target Organs": 2144,
  "Target organ damage": 2145,
  "Temperature sense": 2146,
  "Tendon reflex testing": 2147,
  "Terminal stage": 2148,
  "Testing kidney function": 2149,
  "Testosterone": 2150,
  "The blood uric acid level fluctuates too much in a short period of time": 2151,
  "The bone is a punched-hole defect with sharp edges.": 2152,
  "The continuous improvement of medical care": 2153,
  "The decline in insulin secretion function of \u03b2 cells is more obvious than the decline in insulin sensitivity": 2154,
  "The decline in insulin secretion is more significant than the decline in insulin sensitivity": 2155,
  "The defect is semicircular or continuous arc": 2156,
  "The dorsalis pedis artery pulse is weakened or absent": 2157,
  "The dose remains unchanged or is reduced by 1/3 to 1/2": 2158,
  "The insulin secretion function of \u03b2 cells has begun to gradually decline": 2159,
  "The kidneys gradually shrink": 2160,
  "The pain is unbearable": 2161,
  "The starting dose is 20 mg": 2162,
  "Therapeutic lifestyle changes": 2163,
  "Thiazide diuretics": 2164,
  "Thiazides": 2165,
  "Thiazolidinediones": 2166,
  "Thiazolidinediones (TZDs)": 2167,
  "Ticlopidine": 2168,
  "Tinea pedis": 2169,
  "Tingling in the extremities": 2170,
  "Toe amputation": 2171,
  "Toe compression ischemia": 2172,
  "Toes": 2173,
  "Tolazamide": 2174,
  "Tolbutamide": 2175,
  "Tophi": 2176,
  "Tophi Deposition": 2177,
  "Total Testosterone": 2178,
  "Total serum bilirubin (TBIL)": 2179,
  "Tractional retinal detachment": 2180,
  "Trandolapril": 2181,
  "Transcutaneous oxygen tension": 2182,
  "Transfer": 2183,
  "Transferrin (TRF)": 2184,
  "Transforming Growth Factor Beta 1 (TGF-\u03b21)": 2185,
  "Transience": 2186,
  "Transient": 2187,
  "Transient abdominal pain": 2188,
  "Transient ischemic attack": 2189,
  "Transient steroid-induced diabetes": 2190,
  "Treadmill exercise test": 2191,
  "Trigeminal nerve": 2192,
  "Triglyceride (TG)": 2193,
  "Triglycerides": 2194,
  "Triptolide": 2195,
  "Trochlear nerve": 2196,
  "Tubular atrophy": 2197,
  "Tubular related diseases": 2198,
  "Tubulointerstitial and renal microvascular diseases": 2199,
  "Tubulointerstitial fibrosis": 2200,
  "Tubulointerstitial nephritis": 2201,
  "Tubulointerstitium": 2202,
  "Tumor": 2203,
  "Two-day fasting": 2204,
  "Type 1": 2205,
  "Type 1 and type 2 diabetes": 2206,
  "Type 1 diabetes": 2207,
  "Type 1 diabetes mellitus": 2208,
  "Type 1 diabetes microangiopathy": 2209,
  "Type 1DN": 2210,
  "Type 2": 2211,
  "Type 2 DM": 2212,
  "Type 2 and type 1 diabetes": 2213,
  "Type 2 diabetes": 2214,
  "Type 2 diabetes mellitus": 2215,
  "Type 2 diabetes mellitus (T2DM)": 2216,
  "Type 2 diabetic nephropathy": 2217,
  "Type 2 diabetic retinopathy": 2218,
  "Type A": 2219,
  "Type A insulin resistance syndrome": 2220,
  "Type B": 2221,
  "Type C": 2222,
  "Type III, IV, VII": 2223,
  "UAE": 2224,
  "UAE/AER": 2225,
  "Ulcers that are difficult to heal": 2226,
  "Ulnar nerve": 2227,
  "Ultrasound": 2228,
  "Unilateral knee arthritis": 2229,
  "Unstable": 2230,
  "Unstable angina": 2231,
  "Up to 1.2 U/kg": 2232,
  "Up to 2000 mg/day": 2233,
  "Upper gastrointestinal bleeding": 2234,
  "Upper limb joints": 2235,
  "Upper or middle calyx stones": 2236,
  "Upper respiratory tract infection": 2237,
  "Upregulates endothelin and downregulates nitric oxide synthase expression": 2238,
  "Uprightness": 2239,
  "Urate crystal deposition": 2240,
  "Urate deposition in joint cavity": 2241,
  "Urate deposits in the kidneys": 2242,
  "Urea nitrogen": 2243,
  "Uric acid": 2244,
  "Uric acid clearance": 2245,
  "Uric acid excretion": 2246,
  "Uric acid kidney stones": 2247,
  "Uric acid nephrolithiasis": 2248,
  "Uric acid nephropathy": 2249,
  "Uric acid stones": 2250,
  "Uric acid stones in the urinary tract": 2251,
  "Urinary": 2252,
  "Urinary albumin excretion rate": 2253,
  "Urinary albumin excretion rate (UAER)": 2254,
  "Urinary incontinence": 2255,
  "Urinary system": 2256,
  "Urinary tract": 2257,
  "Urinary tract infection": 2258,
  "Urinary tract obstruction": 2259,
  "Urinary tract stones": 2260,
  "Urine ACR": 2261,
  "Urine albumin": 2262,
  "Urine albumin excretion rate (UAE/AER)": 2263,
  "Urine albumin/creatinine ratio": 2264,
  "Urine albumin/creatinine ratio (ACR)": 2265,
  "Urine microalbumin": 2266,
  "Urine protein": 2267,
  "Urine sugar": 2268,
  "Urine total protein": 2269,
  "Urine uric acid": 2270,
  "Urodynamics": 2271,
  "Urogenital infections": 2272,
  "Urogenital tract": 2273,
  "Urogenital tract infection": 2274,
  "Urticaria": 2275,
  "Use of glucocorticoids": 2276,
  "Vaginal candidiasis": 2277,
  "Valsartan": 2278,
  "Various disorders that may affect the process of digesting food": 2279,
  "Vascular": 2280,
  "Vascular bypass surgery": 2281,
  "Vascular color Doppler examination": 2282,
  "Vascular complications": 2283,
  "Vascular death": 2284,
  "Vascular disease": 2285,
  "Vascular disease of varying degrees": 2286,
  "Vascular endothelial damage": 2287,
  "Vascular events": 2288,
  "Vascular hyalinosis": 2289,
  "Vascular imaging": 2290,
  "Vascular lining": 2291,
  "Vascular occlusion/restenosis": 2292,
  "Vascular patency": 2293,
  "Venlafaxine": 2294,
  "Venous beading": 2295,
  "Venous thrombosis": 2296,
  "Verapamil": 2297,
  "Very low energy diet": 2298,
  "Vibration Sense": 2299,
  "Video disc": 2300,
  "Vigorous exercise": 2301,
  "Vildagliptin": 2302,
  "Vision Network": 2303,
  "Visual impairment": 2304,
  "Vitamin B12": 2305,
  "Vitamin B12 deficiency": 2306,
  "Vitamin D": 2307,
  "Vitamin D and folic acid deficiency": 2308,
  "Vitamin D3": 2309,
  "Vitreous": 2310,
  "Vitreous hemorrhage": 2311,
  "Voglibose": 2312,
  "Vomit": 2313,
  "Vulvovaginal": 2314,
  "Vulvovaginal yeast infection": 2315,
  "Vulvovaginitis": 2316,
  "Warfarin": 2317,
  "Water and sodium retention": 2318,
  "Weak or absent arterial pulse in the extremities": 2319,
  "Weakness": 2320,
  "Weight Management": 2321,
  "Weight control": 2322,
  "Weight control within normal range (BMI 18.5-23.9 kg/m2)": 2323,
  "Weight gain": 2324,
  "Weight loss": 2325,
  "Wet or dry gangrene": 2326,
  "White tofu-like discharge": 2327,
  "With music therapy": 2328,
  "Worry": 2329,
  "Worsening of glucose tolerance": 2330,
  "Wound": 2331,
  "Wound infection": 2332,
  "Xuesetong Injection": 2333,
  "Zn": 2334,
  "a-Glucosidase inhibitors": 2335,
  "acute": 2336,
  "allergy": 2337,
  "anemia": 2338,
  "ankle": 2339,
  "artery": 2340,
  "arthritis": 2341,
  "ascites": 2342,
  "aspirin": 2343,
  "bA1c": 2344,
  "belly": 2345,
  "bladder": 2346,
  "blindness": 2347,
  "blood pressure": 2348,
  "blood sugar": 2349,
  "bone": 2350,
  "brain": 2351,
  "cellulitis": 2352,
  "cholesterol": 2353,
  "coma": 2354,
  "constipate": 2355,
  "continued": 2356,
  "daily": 2357,
  "diabetes": 2358,
  "diarrhea": 2359,
  "diet": 2360,
  "dizziness": 2361,
  "eGFR": 2362,
  "exercise": 2363,
  "fall": 2364,
  "fasting": 2365,
  "fever": 2366,
  "foot": 2367,
  "fracture": 2368,
  "fundus": 2369,
  "gangrene": 2370,
  "glucose": 2371,
  "gout": 2372,
  "heart": 2373,
  "heart disease": 2374,
  "hematuria": 2375,
  "heparin": 2376,
  "hepatitis": 2377,
  "hormone": 2378,
  "hypertension": 2379,
  "indigestion": 2380,
  "injection": 2381,
  "insulin": 2382,
  "irritability": 2383,
  "joint": 2384,
  "karst": 2385,
  "kidney": 2386,
  "knee": 2387,
  "liver": 2388,
  "long": 2389,
  "lose weight": 2390,
  "lung": 2391,
  "marrow": 2392,
  "muscle": 2393,
  "nausea": 2394,
  "nerve": 2395,
  "niacin": 2396,
  "non-HDL-C": 2397,
  "numbness": 2398,
  "obesity": 2399,
  "once": 2400,
  "oral": 2401,
  "osteomyelitis": 2402,
  "overweight": 2403,
  "pain": 2404,
  "palpation": 2405,
  "pancreas": 2406,
  "pancreatitis": 2407,
  "prostate": 2408,
  "qd": 2409,
  "rash": 2410,
  "rectum": 2411,
  "skin": 2412,
  "skin care": 2413,
  "spinal cord": 2414,
  "spine": 2415,
  "sports": 2416,
  "stability": 2417,
  "stomach ache": 2418,
  "stone": 2419,
  "stress-induced hyperglycemia": 2420,
  "sudden death": 2421,
  "tenderness": 2422,
  "thrombus": 2423,
  "thyroid": 2424,
  "toe": 2425,
  "transplant": 2426,
  "trouble breathing": 2427,
  "type 1": 2428,
  "ulcer": 2429,
  "vaginal": 2430,
  "vegetarian diet": 2431,
  "vein": 2432,
  "weak": 2433,
  "\u03b1-Glucosidase inhibitors": 2434,
  "\u03b1-Glucosidase printing agent": 2435,
  "\u03b2-cell dysfunction": 2436,
  "\u03b2-cell insulin secretion function is more obvious than insulin sensitivity": 2437,
  "\u2264 3 times per day": 2438,
  "\u2264 50 mg/day": 2439,
  "\u226410 mg/day": 2440
}